Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a rapidly advancing disease characterized by the clonal expansion of lymphoid precursors in the bone marrow and consequential displacement of normal hematopoietic cells. ALL is the most common type of cancer and leukemia in children in the United States.


Molecular Assays:

BCR-ABL: The BCR-ABL fusion is found in ~25–30% adult ALL and 2–10% of childhood ALL. Detection of the BCR-ABL translocation aids researchers in the classification of disease, prognosis, response to treatment, and the assessment of minimal residual disease (MRD).1,2,3


FISH Assays:

P16 (9p21): Copy number decrease is associated with high grade dysplasia/ adenocarcinoma and increased risk of recurrence.4

Order FISH Probes


    1. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010 Nov 25;116(22):e111-7. Epub 2010 Aug 18.
    2. WHO International Standard. 1st WHO International Genetic Reference Panel for quantitation of BCR-ABL translocation by RQ-PCR.
    3. Hughes T, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
    4. Kees UR, Burton PR, Lü C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997 Jun 1;89(11):4161-6. PubMed PMID: 9166859.